The drugmaker said the results for giredestrant open the door to adding a treatment option at an early stage of the cancer, ...

Roche's ROG.S experimental oral drug giredestrant has been shown to cut the risk of recurrence of a common form of breast ...

Roche has reported another phase 3 win for its oral selective estrogen receptor degrader (SERD). Success at a planned interim ...

Analysts said the deal shows Roche’s long-term strategy for its sequencing technology is “a clinical box for running NGS kits ...

Roche (OTCQX:RHHBY) unit Genentech announced on Tuesday that giredestrant, a selective estrogen receptor degrader (SERD), ...

The partnership will expedite the availability of Freenome's tests in markets outside the U.S, according to the company.

Roche claimed the results make its drug giredestrant the first of its kind, a so-called oral SERD, to show a benefit in the ...

Roche has built the evidence for its oral BTK inhibitor fenebrutinib in multiple sclerosis (MS) with two phase 3 readouts ...

Roche's experimental multiple sclerosis drug achieved its main goal in one of two key late-stage trials testing it against ...

Roche Holding AG said a multiple sclerosis drug showed it could work for most forms of the disease in two late-stage trials, ...

As Roche works to switch certain patients with breast cancer over to a fixed-dose combination of two medicines, its ...